# OrbiMed

> OrbiMed is a VC fund in New York backing Biotechnology and Health Care. See 663 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 663
- Last investment: Jul 2026
- Lead investor: 35%
- Last fund: Aug 2025
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/orbimed-advisors
- X (Twitter): https://twitter.com/OrbiMed
- Website: http://www.orbimed.com
- Facebook: https://www.facebook.com/OrbiMed-Advisors-522321737819113/timeline/

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investmentsseries of venture capital funds and a family of public equity investment funds.

## Contacts

5 contacts available for OrbiMed. Shizune tracks 25 team members at OrbiMed. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/orbimed-advisors?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $10M–$150M |
| Series B | $24M–$150M |
| Series C | $18M–$183M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 288 | 43% |
| Health Care | 220 | 33% |
| Medical | 117 | 18% |
| Pharmaceutical | 110 | 17% |
| Therapeutics | 101 | 15% |

79 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 127 | 19% |
| Series A | 106 | 16% |
| Series C | 85 | 13% |
| Funding Round | 53 | 8% |
| Post-IPO Equity | 53 | 8% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 238 | 36% |
| China | 47 | 7% |
| Israel | 21 | 3% |
| Canada | 12 | 2% |
| United Kingdom | 9 | 1% |

17 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Dina Chaya | Partner | 7 | https://shizune.co/investors/profile/dina-chaya |
| Kevin Koch | Venture Partner | 3 | https://shizune.co/investors/profile/kevin-koch |
| Rishi Gupta | Private Equity Partner | 12 | https://shizune.co/investors/profile/rishi-gupta |
| Sunny Sharma | Senior Managing Director | 10 | https://shizune.co/investors/profile/sunny-sharma |
| Tadd S. Wessel | Managing Director | 10 | https://shizune.co/investors/profile/tadd-s-wessel |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TytoCare | TytoCare is a mobile-health platform and device, allowing anyone to perform self physical examination and remote diagnosis.Tyto Care has three telehealth products: the TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote point-of-care locations. All solutions are designed to replicate a facetious clinician visit andinclude a modular examination tool for examining the heart, lungs, skin, throat, ears, and body temperature; a complete telehealth platform for sharing exam data, conducting live video exams, and scheduling visits; a cloud-based data repository with analytics; and built-in guidance technology and machine learning algorithms to ensure accuracy and ease of use. TytoCare was founded by Dedi Gilad, Ofer Tzadik in 2012 with a vision to put health in the hands of the consumer. | $25M | Venture - Series Unknown | Jul 15, 2026 |  |
| Iswarya Fertility Center | Iswarya Fertility Center provides IVF, IUI, egg donation, azoospermia, ovulation induction, and miscarriage treatment solutions. | $37M | Private Equity | Jul 09, 2026 |  |
| Iswarya Fertility Center | Iswarya Fertility Center provides IVF, IUI, egg donation, azoospermia, ovulation induction, and miscarriage treatment solutions. | $37M | Private Equity | Jul 09, 2026 |  |
| Fore Biotherapeutics | We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M | Series D | Jul 07, 2026 |  |
| Lycia Therapeutics | Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M | Series D | Jun 25, 2026 |  |
| Asian Institute of Medical Sciences | Asian Institute of Medical Sciences is a 425 bedded super specialty hospital in Delhi NCR, India which is dedicated to provide accessible, affordable and best available healthcare services in India. Accredited by NABH and NABL, Asian Hospital Faridabad provides preventive, diagnostic, therapeutic, rehabilitative, palliative and supportive servicesall under one roof and is designed to meet patient care and research requirements of the new millennium.Asian Institute of Medical Sciences offers comprehensive multi-specialty tertiary care facilities through its 14 centres of excellence.- ASIAN CANCER CENTRE - ASIAN CENTRE FOR BONE MARROW TRANSPLANT - ASIAN HEART CENTRE - ASIAN CENTRE FOR ADVANCED SURGERY- ASIAN CENTRE FOR NEUROLOGY AND NEUROSURGERY - ASIAN CENTRE FOR UROLOGY AND KIDNEY TRANSPLANT - ASIAN CENTRE FOR RENAL DISEASES - ASIAN CENTRE FOR BONE AND JOINTS - ASIAN CENTRE FOR ADVANCED IMAGING - ASIAN CENTRE FOR GASTROENTEROLOGY - ASIAN CENTRE FOR MOTHER AND CHILD- ASIAN CENTRE FOR BARIATRIC & METABOLIC SURGERY - ASIAN CENTRE FOR AESTHETIC SURGERY & MEDICINE - ASIAN IVF CENTRE | $44M | Debt Financing | Jun 19, 2026 |  |
| TruNativ | Trunative is a producer and distributor of nutrition products under the TruNativ brand targetting health and fitness enthusiasts. | $30M | Series B | Jun 16, 2026 |  |
| TruNativ | Trunative is a producer and distributor of nutrition products under the TruNativ brand targetting health and fitness enthusiasts. |  | Secondary Market | Jun 16, 2026 |  |
| Q32 Bio | Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $55M | Post-IPO Equity | May 26, 2026 |  |
| Accro Bioscience | Accro Bioscience research centers on the molecular mechanism of regulated cell death such as necroptosis, pyroptosis, and ferroptosis. | $50M | Series C | May 18, 2026 |  |

10 of 663 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 87 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 42 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 41 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 41 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 39 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 39 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)

## FAQ

### What does OrbiMed invest in?

OrbiMed invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 663 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is OrbiMed's check size?

OrbiMed typically joins rounds of $10M–$150M at Series A, $24M–$150M at Series B and $18M–$183M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds OrbiMed participates in.

### How do I contact OrbiMed?

Public channels for OrbiMed include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at OrbiMed?

The team at OrbiMed includes Dina Chaya (Partner), Kevin Koch (Venture Partner) and Rishi Gupta (Private Equity Partner), among 25 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co